
- Volume 0 0
Pancreatic Cancer Trials Offer Positive Results
Data from phase 3 clinical trials on theuse of Virulizin for treating pancreaticcancer revealed a significant survival benefitfor a particular subgroup of patients.The randomized, double-blind, multicentertrial compared Virulizin plus gemcitabinewith placebo plus gemcitabine inchemo-naive patients with locally advancedor metastatic pancreatic cancer.As a first-line treatment, Virulizin did notshow any statistical significance in overallsurvival, but it showed encouraging survivalrates among patients with metastasisand patients with low EasternCooperative Oncology Group performancestatus. A more recent data analysisshowed increased survival benefit forpatients taking Virulizin who received theoptional second-line therapy after diseaseprogression. At this stage, patientswho remained on Virulizin had a mediansurvival of 10.9 months, compared with7.4 months for patients taking placebo.
The results were presented onFebruary 1, 2006, at the 17th InternationalCongress on Anti-Cancer Treatment inParis, France. Jim Wright, PhD, chief executiveofficer of the drug's manufacturer,Lorus Therapeutics Inc, noted: "Virulizinsignificantly improved survival in pancreaticcancer patients who remained in thetreatment arm even when treatment withthe standard-of-care chemotherapy gemcitabinewas no longer effective. Althoughthis finding is from exploratory analysis, itprovides important new information.
Ms. Farley is a freelance medicalwriter based in Wakefield, RI.
Articles in this issue
over 19 years ago
Should Pharmacists Receive Overtime Pay?over 19 years ago
Pharmacists—Cops or Not? (Part 2)over 19 years ago
canyouREADtheseRxs?over 19 years ago
compoundingHOTLINEover 19 years ago
NSAIDs and Antihypertensive Agentsover 19 years ago
FDA Approves New Constipation Drugover 19 years ago
Angina Drug Approvedover 19 years ago
Cancer Drug Receives Approval for 2 Conditionsover 19 years ago
Long-term LNG/EE Use Does Not Hinder Future Ovulationover 19 years ago
Compounding for Vaginal ConditionsNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.